Results 101 to 110 of about 27,286 (132)

Genetics and regulation of angiopoietin-like proteins 3 and 4

Current Opinion in Lipidology, 2006
Lipoprotein lipase activity in a given tissue is the rate limiting step for the uptake of triglyceride-derived fatty acids. Imbalances in the partitioning of fatty acids have major metabolic consequences. Given the central role of lipoprotein lipase in energy metabolism, the discovery of new molecules that affect the activity of lipoprotein lipase ...
openaire   +2 more sources

Antibodies to human angiopoietin-like protein 3: a patent evaluation of WO2012174178

Expert Opinion on Therapeutic Patents, 2013
The patent WO2012174178 claims the effect of a fully human antibody or antigen-binding fragment of a human antibody which specifically binds and neutralizes, inhibits, blocks, abrogates, reduces or interferes with the activity of human angiopoietin-like protein 3 (hANGPTL3).
Katsuyuki, Nakajima, Junji, Kobayashi
openaire   +2 more sources

Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia

Current Atherosclerosis Reports, 2023
The role of the inhibition of ANGPTL3 in severe or refractory hypercholesterolemia is well documented, less in severe hyperTG. This review focuses on the preclinical and clinical development of ApoC-III inhibitors and ANGPTL3, 4, and 3/8 complex inhibitors for the treatment of severe or refractory forms of hypertriglyceridemia to prevent cardiovascular
Miriam, Larouche, Etienne, Khoury, Diane, Brisson, Daniel, Gaudet   +3 more
openaire   +2 more sources

Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia

Current Opinion in Endocrinology, Diabetes & Obesity
Purpose of review To summarize recent advances in therapeutic strategies targeting angiopoietin-like protein 3 (ANGPTL3), a central regulator of triglyceride and remnant lipoprotein metabolism, and to discuss the potential of emerging pharmacologic approaches
Pablo, Corral, Natalia, Nardelli, Laura, Schreier   +2 more
openaire   +2 more sources

Future of angiopoietin-like protein 3 inhibitors as a therapeutic agent

Current Opinion in Lipidology
Purpose of review Triglyceride-rich lipoproteins (TRLs) and LDL remain major drivers of atherosclerotic cardiovascular disease, and angiopoietin-like protein 3 (ANGPTL3) has emerged as a promising target to lower both triglycerides and LDL cholesterol (LDL-C).
Nicholas A, Marston, André, Zimerman
openaire   +2 more sources

Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment

Cardiology in Review, 2019
Angiopoietin-like 3 protein (ANGPTL3) is an inhibitor of both lipoprotein lipase and endothelial lipase in humans. Population studies indicate a relationship between loss of function mutations in ANGPTL3 and favorable reductions in triglycerides and non- high-density lipoprotein cholesterol.
William, Lang, William H, Frishman
openaire   +2 more sources

Angiopoietin-like protein 3, a hepatic secretory factor, activates lipolysis in adipocytes

Biochemical and Biophysical Research Communications, 2003
Our previous work identified a genetic mutation in the gene encoding angiopoietin-like protein 3 (Angptl3) in KK/Snk mice (previously KK/San), a mutant strain of KK obese mice. KK/Snk had significantly lower plasma triglyceride and free fatty acid (FFA) than KK mice. Human ANGPTL3 treatment increased both plasma triglyceride and FFA.
Mitsuru, Shimamura, Morihiro, Matsuda, Sachiko, Kobayashi, Yosuke, Ando, Mitsuru, Ono, Ryuta, Koishi, Hidehiko, Furukawa, Makoto, Makishima, Iichiro, Shimomura   +8 more
openaire   +2 more sources

Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia

Atherosclerosis, 2009
Angiopoietin-like protein 3, a liver-derived plasma protein, increases plasma triglycerides (TG) in mice by suppressing the activity of lipoprotein lipase, a key enzyme in plasma TG clearance. Uremic dyslipidemia is characterized by increased TG-rich lipoproteins such as very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL ...
Tetsuo, Shoji, Sawako, Hatsuda, Shoko, Tsuchikura, Eiji, Kimoto, Ryusuke, Kakiya, Hideki, Tahara, Hidenori, Koyama, Masanori, Emoto, Tsutomu, Tabata, Yoshiki, Nishizawa   +9 more
openaire   +2 more sources

Molecular characterization and expression of angiopoietin-like protein 3 in the chicken, Gallus gallus

General and Comparative Endocrinology, 2008
Angiopoietin-like protein 3 (ANGPTL3) is a 70 kDa secretory glycoprotein, which has been identified as a plasma triacylglycerol (TG)-increasing factor in KK/San mice. In this study, we have characterized the expression profile and activity of ANGPTL3 in the chicken, Gallus gallus.
Kan, Sato, Hyang Sook, Seol, Kumiko, Sato, Tosihiko, Kamada, Yukio, Akiba   +4 more
openaire   +2 more sources

Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors

American Journal of Cardiovascular Drugs
Hypertriglyceridemia has been proposed as a risk factor for atherosclerotic cardiovascular disease (ASCVD). Triglycerides (TG) are viewed as a marker for remnant cholesterol in triglyceride-rich lipoproteins, as this remnant cholesterol has been identified as a causal risk factor for ASCVD. The limited number of effective treatments for elevated TG has
Taha Mansoor, Vijay Nambi, Sachin Parikh, Arunima Misra, Mahmoud Ismayl, Claire Sullivan, Laurence Sperling, Salim S. Virani, Mahmoud Al Rifai, Santhosh K. G. Koshy, Dmitry Abramov, Abdul Mannan Khan Minhas   +11 more
openaire   +2 more sources